Keyphrases
Doxorubicin
100%
Polytherapy
100%
Small Cell Sarcoma
100%
Vorinostat
55%
17-DMAG
55%
Sorafenib
44%
Abacavir
33%
Apoptosis
22%
Monotherapy
22%
Sarcoma Cells
22%
Targeted Agents
22%
Combination Index
22%
Chemotherapy
11%
Telomerase
11%
Cytotoxicity
11%
Cell Viability
11%
Cell Killing
11%
Targeted Therapy
11%
Tyrosine Kinase Inhibitor
11%
Histone Deacetylase Inhibitor (HDACi)
11%
Propidium Iodide
11%
Heat Shock Protein 90 (Hsp90)
11%
Annexin V Staining
11%
Life Cycle Analysis
11%
Rhabdomyosarcoma
11%
Triple Therapy
11%
Caspase 3/7 Activity
11%
Undifferentiated Sarcoma
11%
Viability Cell
11%
Advanced Sarcoma
11%
Additive Combination
11%
MTS Assay
11%
Ewing Sarcoma
11%
Dual-target
11%
Targeted Combination Therapy
11%
Medicine and Dentistry
Combination Therapy
100%
Doxorubicin
100%
Small Cell Sarcoma
100%
17-Dimethylaminoethylamino-17-Demethoxygeldanamycin
55%
Vorinostat
55%
Sorafenib
44%
Abacavir
33%
Programmed Cell Death
22%
Sarcoma Cell Line
22%
Monotherapy
22%
Connective Tissue Cancer
22%
Cell Line
11%
Cytotoxicity
11%
Targeted Therapy
11%
Cell Viability
11%
Tyrosine-Kinase Inhibitor
11%
Caspase 3
11%
Histone Deacetylase Inhibitor
11%
Telomerase
11%
Lipocortin 5
11%
Rhabdomyosarcoma
11%
Cell Killing
11%
Cell-Cycle Analysis
11%
Propidium Iodide
11%
Ewing Sarcoma
11%
Antibiotic A204
11%
MTS Assay
11%